[artículo] 
inJournal of Clinical Psychopharmacology > Año 2009 - Vol. 29 - No. 6 (Diciembre) . - pp. 561-564

Título :	A randomized controlled trial of atomoxetine in generalized social anxiety disorder
Tipo de documento:	texto impreso
Autores:	Lakshmi N. Ravindran, Autor ; Daniel S. Kim, Autor ; Andrea M. Letamendi, Autor
Fecha de publicación:	2022
Artículo en la página:	pp. 561-564
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Atomoxetina, Trastorno de ansiedad social, Fobia social, Farmacoterapia
Resumen:	The current mainstays of social anxiety disorder pharmacotherapy are serotonergic agents, with less known about the efficacy of more noradrenergic drugs. Atomoxetine (ATM), a highly selective norepinephrine reuptake inhibitor, is currently approved for the treatment of attention-deficit/hyperactivity disorder (ADHD).
Link:	./index.php?lvl=notice_display&id=29480

[artículo] A randomized controlled trial of atomoxetine in generalized social anxiety disorder [texto impreso] / Lakshmi N. Ravindran, Autor ; Daniel S. Kim, Autor ; Andrea M. Letamendi, Autor . - 2022 . - pp. 561-564.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2009 - Vol. 29 - No. 6 (Diciembre) . - pp. 561-564

Palabras clave:	Atomoxetina, Trastorno de ansiedad social, Fobia social, Farmacoterapia
Resumen:	The current mainstays of social anxiety disorder pharmacotherapy are serotonergic agents, with less known about the efficacy of more noradrenergic drugs. Atomoxetine (ATM), a highly selective norepinephrine reuptake inhibitor, is currently approved for the treatment of attention-deficit/hyperactivity disorder (ADHD).
Link:	./index.php?lvl=notice_display&id=29480